Properties
What is it?
What is Cogniver and what is it used for? Cogniver 100 mg/2 ml solution for injection for IM and IV use contains ethylmethylhydroxypyridine succinate as the active substance. Ethylmethylhydroxypyridine succinate is characterized by antioxidant (inhibiting free radical formation), antihypoxic (promoting increased oxygen levels in the blood), membrane-protective, nootropic (enhancing brain functions such as learning, memory, attention, and consciousness), anticonvulsant (involuntary muscle contractions), anxiolytic (treating anxiety and fear), and hypolipidemic (reducing lipid levels in the body) action. Cogniver 100 mg/2 ml solution for injection for IM and IV use consists of 10 ampoules of 2 ml Type I glass placed in a cardboard box. Cogniver is used to treat the following conditions: • Acute conditions caused by thrombosis of cerebral blood vessels or bleeding from cerebral blood supply vessels (acute cerebrovascular disorders); • Craniocerebral trauma; • Consequences of craniocerebral trauma; • Brain damage due to circulatory disorders (encephalopathy); • Muscle tremors, involuntary contractions, spasms caused by damage to the nervous and cardiovascular systems (neurocirculatory dystonia); • Impaired brain function due to atherosclerosis (mild cognitive impairment); • Anxiety, fear caused by nervous diseases; • Complex therapy of acute myocardial infarction (from the first day); • Relief of symptoms of alcohol dependence, predominantly manifested by neurosis and vegetative-vascular disorders; • Acute intoxication caused by antipsychotic drugs; • Complex therapy of acute purulent inflammatory diseases of the abdominal cavity (acute necrotic pancreatitis, peritonitis); • Complex treatment of various stages of primary open-angle glaucoma (increased intraocular pressure). 2. Special warnings Before taking Cogniver Do not take Cogniver if • you are hypersensitive (allergic) to the active substance, ethylmethylhydroxypyridine succinate • you have acute liver and/or kidney dysfunction • you are pregnant • you are breastfeeding Cogniver is not used in children and adolescents under 18 years of age. Take special precautions when using Cogniver in the following cases: If you have any of the listed conditions, consult your doctor before taking Cogniver: Individuals prone to asthmatic attacks and hypersensitive to sulfates may develop a severe allergic reaction. Consult your doctor if you experience any of the above symptoms or have a history of them. Taking Cogniver with food and drink Due to the method of administration of Cogniver, interaction with food and drink is not expected. Pregnancy Before taking the preparation, consult your doctor or pharmacist. Cogniver must not be taken during pregnancy. Women of childbearing potential should use effective contraception during treatment. If pregnancy is detected during treatment, consult your doctor or pharmacist immediately. Lactation Before taking the preparation, consult your doctor or pharmacist. Cogniver must not be taken during lactation. Driving and operating machinery Caution is required when driving and operating machinery that requires particular caution and rapid psychomotor reactions during Cogniver treatment. Important information about the excipients of Cogniver Cogniver does not contain any excipients that require special precautions. Interactions with medicines Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription and herbal preparations. Consult your doctor if you are taking any of the following preparations: • Benzodiazepines or anxiolytics used to treat anxiety, insomnia (sleep-wake disorders); • Anticonvulsants (e.g., carbamazepine) used to treat epilepsy; • Antiparkinsonian drugs (e.g., levodopa) used to treat Parkinson's disease. Cogniver enhances the effects of nitrates and reduces the effects of preparations containing ethanol. Tell your doctor or pharmacist if you are taking or have recently taken any other prescription or over-the-counter medicines. 3. How to take Cogniver Dosage / Method of administration: Acute thrombosis or bleeding of cerebral blood vessels and symptoms associated with damage to the affected area of the brain (acute cerebrovascular disorders): Cogniver is administered IV at a dose of 200-500 mg 2-4 times a day for the first 10-14 days, then IM at 200-250 mg 2-3 times a day for 2 weeks. Craniocerebral trauma and its consequences: Cogniver is administered IV at a dose of 200-500 mg 2-4 times a day for 10-15 days. Vascular encephalopathy in the decompensation phase: Cogniver is administered IV at a dose of 200-500 mg 1-2 times a day for 14 days, as a bolus or infusion, then IM at 100-250 mg/day for the next 2 weeks. Prevention of brain damage due to circulatory disorders (encephalopathy): Cogniver is administered IM at a dose of 200-250 mg twice a day for 10-14 days. Muscle tremors, involuntary contractions, spasms caused by damage to the nervous and vascular systems (neurocirculatory dystonia) and anxiety and fear associated with nervous diseases: Cogniver is administered IM at a dose of 50-400 mg/day for 14 days. Impaired brain function due to atherosclerosis (mild cognitive impairment), anxiety and fear: Cogniver is administered by IM injection at 100-300 mg/day for 14-30 days. Complex therapy of acute myocardial infarction (from the first day): Cogniver is administered by IV and IM injection for 14 days in combination with traditional treatment for myocardial infarction, which includes nitrates, beta-blockers, ACE inhibitors, thrombolytics, anticoagulants, and antiplatelets, as well as other symptomatic agents. For maximum effect, it is advisable to administer Cogniver intravenously for the first 5 days, and intramuscularly for the next 9 days. During IV infusion, Cogniver is administered slowly, dropwise (to avoid side effects), diluted in 100-150 ml of 0.9% sodium chloride or 5% dextrose (glucose) solution, over 30-90 minutes. If necessary, slow down bolus administration to at least 5 minutes. The preparation is administered (IV or IM) 3 times a day at 8-hour intervals. The therapeutic dose is 6-9 mg/kg body weight per day, single dose – 2-3 mg/kg body weight. The maximum daily dose should not exceed 800 mg, and the single dose – 250 mg. Relief of symptoms of alcohol dependence, predominantly manifested by neurosis and vegetative-vascular disorders (abstinence): Cogniver is administered by IV drip or IM at 200-500 mg 2-3 times a day for 5-7 days. Acute intoxication caused by antipsychotic drugs: Cogniver is administered intravenously at 200-500 mg/day for 7-14 days. Complex therapy of acute purulent inflammatory diseases of the abdominal cavity (acute necrotic pancreatitis, peritonitis): Cogniver is administered on the first night, preoperatively and postoperatively. The dose depends on the type and course of the disease, the route of administration, and the characteristics of the clinical course. Withdrawal of Cogniver should be gradual only after solid clinical and laboratory improvement. Acute interstitial pancreatitis: Cogniver is administered by IV drip (in 0.9% sodium chloride solution) at 200-500 mg 3 times a day and IM. Mild necrotic pancreatitis: Cogniver is administered by IV drip (in 0.9% sodium chloride solution) at 100-200 mg 3 times a day and IM. Moderate necrotic pancreatitis: Cogniver is administered by IV drip (in 0.9% sodium chloride solution) at 200 mg 3 times a day. Severe necrotic pancreatitis: Cogniver is administered at 800 mg on the first day divided into 2 doses, then 200-500 mg twice a day, with a gradual reduction in the daily dose. Very severe necrotic pancreatitis: The initial dose of Cogniver is 800 mg/day to manage pancreatogenic shock, and after stabilization of the condition, 300-500 mg twice a day by IV drip (in 0.9% sodium chloride solution), with a gradual reduction in the daily dose. Complex treatment of various stages of primary open-angle glaucoma (increased intraocular pressure): Cogniver is administered by IM injection at 100-300 mg/day 1-3 times a day for 14 days. The maximum daily dose should not exceed 1200 mg. Method of administration: Cogniver is administered by IV or IM injection (bolus or infusion). The infusion solution is diluted in 0.9% sodium chloride or 5% glucose (dextrose) solution. Continuous infusion: Cogniver is administered slowly over 5-7 minutes. Drip infusion: Cogniver is administered at a rate of 40-60 drops/minute. Different age groups: Use in children: Cogniver is not prescribed for children and adolescents under 18 years of age. Use in geriatrics: Patients over 65 years of age should consult their doctor before taking Cogniver. Special populations: Renal dysfunction: Use of Cogniver is not permitted in acute renal dysfunction. Hepatic dysfunction: Use of Cogniver is not permitted in acute hepatic dysfunction. If you think the effect of Cogniver is too strong or too weak, consult your doctor or pharmacist. In case of overdose of Cogniver If you have taken too much Cogniver, consult your doctor or pharmacist. In case of a missed dose of Cogniver Do not take a double dose to make up for a missed dose. Discontinuation of Cogniver Always take Cogniver as directed by your doctor. If you have any questions about taking the medication, consult your doctor or pharmacist. 4. Possible side effects Like all medicines, Cogniver can cause side effects, especially in patients with increased sensitivity to it. Stop taking Cogniver immediately and consult your doctor if you experience any of the following symptoms after taking the medication. You may need urgent medical attention: • Swelling of the hands, feet, ankles, face, lips, or especially the mouth or throat, which makes breathing and swallowing difficult. These events are serious. In case of serious side effects, you may require medical intervention or hospitalization. Side effects are divided into the following categories: Very common: (≥1/10) Common: (≥1/100 - <1/10) Uncommon: (≥1/1000 - <1/100) Rare: (≥1/10000 - <1/1000) Very rare: (<1/10000) Unknown: Frequency is unknown based on available data Unknown • Nausea • Dry mouth • Headache • Dizziness If you experience any side effects not listed in this leaflet, consult your doctor or pharmacist. 5. Storage conditions for Cogniver Keep out of reach of children. Store at a temperature not exceeding 25°C. Use according to the expiry date indicated on the box. Do not use the preparation after the expiry date indicated on the box. Dispensing category Pharmaceutical product group III, available without a prescription.